FAQ

FAQ

It’s an 8 year old science and technology.   Pharmacogenetics is   the study of how a person’s genetic makeup affects the metabolism of medications.  PGx testing can mean the difference between a treatment failure and a successful outcome. While one treatment approach may work well for one individual, the same approach may not be effective or may cause adverse drug effects in other patients. PGx reports CYP genetic variants in patients as extensive metabolizers (EM), poor metabolizers (PM), intermediate metabolizers (IM), or ultra-rapid metabolizers (UM) for their varying   degrees of drug metabolizing abilities. Extensive metabolizers have normal drug metabolism. Poor metabolizers have no or very low metabolism; intermediate metabolizers have reduced metabolism; and ultra-rapid metabolizers have higher than normal drug metabolism. This is critical information to have BEFORE prescribing. And, of course, there is no cost to the doctor for implementing this test. Tragically, adverse drug reactions are now the 4th leading cause of death in America with over 125,000 people dying and 2 million hospitalized each year.
Pharmacogenomic testing predicts how individuals will respond to medication. It is recommended for any patient who is receiving or will receive medications that have pharmacogenomic biomarkers indicated in their labeling.
PGxOne™ Plus comprehensively screens 50 well-established pharmacogenomic genes, provides recommendations for over 220 commercial drugs and a comprehensive coverage of ~200 genetic variants in a single, cost-effective test that provides medically actionable and clinically relevant data. This allows physicians to make effective treatment decisions for their patients. The test utilizes Next Generation Sequencing technology and provides information for individual patient responses to over 200 FDA approved drugs. All drugs covered by the PGxOne Plus test have been endorsed by the FDA (Food and Drug Administration), EMA (European Marketing Authority) and/or the CPIC (Clinical Pharmacogenetics Implementation Consortium), an organization that provides clinical guidelines and recommendations on pharmacogenomics.  PGxOne Plus results provide physicians with concise, medically actionable information about a patient’s genotype, thus allowing them to make effective treatment decisions. Because a patient's genotype remains constant, PGxOne Plus results can be used to inform medical treatment throughout their lifetime.

PharmGKB is a pharmacogenomics knowledge resource that encompasses clinical information including dosing guidelines, drug labels, potentially clinically actionable gene-drug associations and genotype-phenotype relationships. It is a publicly available tool developed by Stanford University with funding from the NIH.
https://www.pharmgkb.org/index.jsp

PGxOne Plus™ covers 50 genes in numerous therapeutic areas including (but not limited to) psychiatry, cardiology, gastroenterology, neurology, rheumatology, oncology, hematology, women’s health, infectious disease, and endocrinology. Any patient that has been diagnosed with, or is currently being treated for a disease within any of these therapeutic categories will benefit from the test.

ABCB1

ACE

ADRA2A

AGTR1

ANKK1

APOE

ATM

CDA

CES1

CNR1

COMT

CYP1A2

CYP2B6

CYP2C19

CYP2C8

CYP2C9

CYP2D6

CYP3A4

CYP3A5

CYP4F2

DPYD

DRD1

DRD2

ERCC1

F2

F5

FAAH

G6PD

GRIK4

GSTP1

HLA-B

HTR1A

HTR2A

HTR2C

IFNL3

ITPA

KIF6

MTHFR

NAT2

NOS1AP

NQO1

OPRM1

SCN2A

SLC6A4

TPMT

UGT1A1

UGT2B15

VKORC1

XRCC1

PGxOne Plus™ testing uses DNA isolated from buccal cells. Two buccal swabs are provided in the PGxOne PLus™ test kit sent to the physician by Admera Health. Both swabs should be used to obtain buccal cells from the patient’s cheeks according to the instructions in the test kit. The swabs should be placed into the collection tube as indicated, and sent back to Admera Health via the return, pre-paid packet provided.

Test results will typically be available within 7-10 business days following receipt of the patient sample.
The sequencing data obtained during the test process will be analyzed by the Admera Health Bioinformatics group using proprietary algorithms. Admera Health will interpret the results and present it to the physician in a clear, concise, and easy to understand format that is evidence-based and clinically actionable.
PGxOne Plus™ sequencing data (variant detection) was validated by direct comparison to data generated by Sanger sequencing. PGxOne Plus™ displayed 100% sensitivity (true positive detection rate) and 100% specificity (true negative detection rate). PGxOne Plus™ accuracy was determined at >99.99% with 66296 of 66289 bases in the Sanger data set correctly called using PGxOne Plus™ data.
Your MedXPrime representative can enroll you as a client of our lab with a simple one page form.

WordPress Image Lightbox Plugin